Journal of Clinical Medicine
Cure8 research brief
Why This Matters
A locally delivered rifamycin formulation reduced macroscopic and microscopic colonic damage in an acute rat model of colitis, suggesting a potential new local therapeutic approach worth further preclinical evaluation.
Who Should Pay Attention
Researchers and clinicians focused on ulcerative colitis drug development; patients following experimental IBD therapies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The study used an acute oxazolone model in rats and compared intracolonic CB-01-35 to vehicle, oral mesalamine (Asacol), and dexamethasone over three days. CB-01-35 significantly lowered the macroscopic damage score and improved histology (less leukocyte infiltration and epithelial damage); body weight and colon weight were not changed.
Authors frame this as an initial proof-of-concept that requires larger and mechanistic follow-up studies.
Keep In Mind
Findings are from an acute oxazolone-induced rat model and are preliminary; animal results do not predict human efficacy or safety. Further mechanistic and larger studies are needed.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJournal of Clinical Medicine
PublisherMDPI AG
AuthorsKatia Mangano, Gian Marco Leone, Roberto Di Marco +5 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedAug 19, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Amelioration of Acute Oxazolone-Induced Colitis via Oral Administration of EPICERTIN, a Mucosal Healing Biotherapeutic for Inflammatory Bowel Disease
The study presents preclinical data that an orally delivered biotherapeutic (EPICERTIN) promotes epithelial repair and reduces inflammation in a UC-relevant mouse model — a potential step toward therapies that directly...
Norcantharidin Ameliorates Experimental Ulcerative Colitis Through Epigenetic and Metabolic Reprogramming Involving IL-6/DNMT1/SOCS3 and AMPK/SIRT1/FOXO3a-Nrf2 Signaling
The study identifies a candidate compound (NCTD) that reduced inflammation and tissue damage in a rat ulcerative colitis model and implicates specific inflammatory, epigenetic, metabolic, and antioxidant pathways —...
Targeted β‐Glucan‐Veiled Oral Apremilast Nanotherapy Modulates Key Dysbiosis‐Associated Gut Microbiota and Alleviates Ulcerative Colitis‐Associated Anxiety, Depression, and Neuropsychiatric Behaviors
The study describes a new oral nanotherapy that delivered apremilast to the inflamed colon in mice and reportedly reduced gut inflammation and behaviors resembling anxiety/depression—suggesting a combined...